The long awaited results of the adjuvant BILCAP study

Discussion Board Forums Clinical Trials The long awaited results of the adjuvant BILCAP study

Viewing 4 posts - 16 through 19 (of 19 total)
  • Author
    Posts
  • #94975
    gavin
    Moderator

    Just noticed that you posted this Marion, thanks! I posted something from CRUK today as well under the chemo board. Great news this is and long awaited too!

    Hugs,

    Gavin

    #94974
    marions
    Moderator

    You are welcome, Mary. Seems this study took 10 years and as Prof. Primrose mentioned, a bit too long. I may see him at ASCO and ask how long it will take to identify the specific subgroup results.
    The next study we are awaiting results from is the Attica-1 study. But at this point they are still in the recruiting stage.
    https://clinicaltrials.gov/ct2/show/NCT02170090

    The last time I spoke with the PI leading this study he mentioned a possible addition of an immune checkpoint inhibitor, but I don’t see any changes made to the original protocol. Hoping to find out more while at ASCO.

    Hugs
    Marion

    #94973
    bglass
    Moderator

    Marion, thank you for posting. This is amazing news. I guess the docs can no longer say there is “no benefit” to adjuvant treatment after resection. Regards, Mary

    #13336
    marions
    Moderator

    This study included gall bladder cancer. Capecitabine is Xeloda.

    “In the subgroup of 430 patients who received treatment per study protocol, capecitabine was associated with a 25% lower chance of death than observation, and this difference was statistically significant”, said Dr. Primrose, the lead study author.

    Important for us to know: which group benefitted most. This data has not yet been evaluated, but the authors are in the process of doing so.

    http://www.ascopost.com/News/55631?utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=6622854

    Marion

Viewing 4 posts - 16 through 19 (of 19 total)
  • The forum ‘Clinical Trials’ is closed to new topics and replies.